Trevena (TRVN) Stock Price, News & Analysis

Company Overview

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.

Key Stats

• Today's Range: $4.00 to $4.93
• 50-Day Range: $0.01 to $7.84
• 52-Week Range: $3.35 to $25.75
• Volume: 43,776 shs
• Average Volume: 25,646 shs
• Market Capitalization: $3.41 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.00
• Consensus Rating: Buy

Trevena Stock Analysis - MarketRank™

Trevena scored higher than 19% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.5 / 5
• Analyst Rating: Buy

Consensus Rating

Trevena has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Trevena has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Trevena is -1.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Trevena is -1.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.41% of the float of Trevena has been sold short.

Short Interest Ratio / Days to Cover

Trevena has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Trevena has recently increased by 24.07%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Trevena does not currently pay a dividend.

Dividend Growth

Trevena does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.41% of the float of Trevena has been sold short.

Short Interest Ratio / Days to Cover

Trevena has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Trevena has recently increased by 24.07%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.2 / 5
• News Sentiment: N/A

News Sentiment

Trevena has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Trevena this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Trevena insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.40% of the stock of Trevena is held by insiders.

Percentage Held by Institutions

Only 13.56% of the stock of Trevena is held by institutions.

TRVN Stock Analysis - Frequently Asked Questions

How have TRVN shares performed this year?

Trevena's stock was trading at $0.7221 at the beginning of the year. Since then, TRVN shares have increased by 516.3% and is now trading at $4.45.
View the best growth stocks for 2024 here.

How were Trevena's earnings last quarter?

Trevena, Inc. (NASDAQ:TRVN) released its earnings results on Thursday, August, 8th. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.37) by $0.36. The biopharmaceutical company had revenue of $0.33 million for the quarter.

When did Trevena's stock split?

Shares of Trevena reverse split on the morning of Tuesday, August 13th 2024. The 1-25 reverse split was announced on Thursday, August 8th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

How do I buy shares of Trevena?

Shares of TRVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Trevena own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Trevena investors own include Conatus Pharmaceuticals (CNAT), Novavax (NVAX), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), SCYNEXIS (SCYX), Matinas BioPharma (MTNB) and Zosano Pharma (ZSAN).

Company Calendar

• Last Earnings: 8/08/2024
• Today: 9/20/2024
• Next Earnings (Estimated): 11/12/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TRVN
• CUSIP: N/A
• CIK: 1429560
• Web: www.trevena.com
• Phone: (610) 354-8840
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $5.00
• High Stock Price Target: $5.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: +13.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.68)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-40,290,000.00
• Net Margins: N/A
• Pretax Margin: -8,339.41%
• Return on Equity: -1,018.15%
• Return on Assets: -105.93%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.46
• Quick Ratio: 3.46

Sales & Book Value

• Annual Sales: $3.12 million
• Price / Sales: 1.20
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($11.07) per share
• Price / Book: -0.40

Miscellaneous

• Outstanding Shares: 850,000
• Free Float: 17,901,000
• Market Cap: $3.73 million
• Optionable: Optionable
• Beta: 1.03